血清三项指标联合检测在原发性肝癌诊断中的应用  

Clinical Application of Combined Determination of AFP,CA125 and CA199 in the Diagnosis of Primary Hepatic Carcinoma

作　　者：魏哲花[1] 

机构地区：[1]无锡市人民医院,江苏无锡214023

出　　处：《实用医技杂志》2008年第31期4345-4346,共2页Journal of Practical Medical Techniques

摘　　要：目的:探讨血清甲胎蛋白(AFP)、糖类抗原125(CA125)、糖类抗原199(CA199)联合检测在原发性肝癌(PHC)诊断中的价值。方法:110例原发性肝癌(PHC)、101例良性肝病患者和100例正常对照组人员的血清AFP、CA125、CA199三项指标采用电化学发光免疫分析法(ECLIA)测定。结果:PHC患者组三项指标均显著高于良性肝病组和正常对照组(P均<0.01);三项指标联合检测诊断PHC的阳性检出率为91.8%,明显高于单项指标的阳性检出率。结论:血清AFP、CA125、CA199联合检测可以提高PHC诊断的敏感性,有助于PHC的早期诊断。Objective To explore the clinical value of combined determination of serum AFP,CA125 and CA199 levels in patients with primary hepatic carcinoma（PHC）. Methods The serum AFP,CA125 and CA199 levels were detected in 110 patients with PHC , 101 patients with other liver diseases and 100 healthy controls by electrochemiluminescence immunoassay. Results The serum AFP ,CA125 and CA199 levels in patients with PHC were significantly higher than those in patients with other liver diseases and healthy controls. The positive rate of combined determination of AFP,CA125 and CA199 in the diagnosis of PHC was 91.8%, it＇ s significantly higher than that of simply determination of those. Conclusion The combined determination of AFP,CA125 and CA199 could significantly improve the sensitivity of the diagnosis of PHC. Combinative detection of AFP,CA125 and CA199 was beneficial to the early diagnosis of PHC.

关 键 词：甲胎蛋白 糖类抗原125 糖类抗原199 原发性肝细胞癌 

分 类 号：R735.7[医药卫生—肿瘤]